Plasma cell leukemia. Ravinet A et al. Bull Cancer. 2014 Nov 1;101(11):1048-1058. A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Kalff A et al. Haematologica. 2014 Nov 7. pii: haematol.2014.111385. [Epub ahead of print]. Solitary extramedullary plasmocytoma of the thyroid: a case report and histological approach to plasma cells infiltrate in the thyroid gland. Wilmars MM et…
DetailsPhase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Tolcher AW et al. Cancer Chemother Pharmacol. 2014 Nov 25. [Epub ahead of print]. Panobinostat: a review of trial results and future prospects in multiple myeloma. Libby EN et al. Expert Rev Hematol. 2014 Nov 20:1-10. [Epub ahead of print].…
DetailsTreatment of multiple myeloma bone disease: experimental and clinical data. Papamerkouriou YM et al. Expert Opin Biol Ther. 2014 Nov 12:1-18. [Epub ahead of print]. Bisphosphonates in multiple myeloma: a fractured consensus. Kumar SK. Leuk Lymphoma. 2014 Nov 5:1-2. [Epub ahead of print]. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Berenson JR et al. Support Care…
DetailsThe potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods. Kontodimopoulos N. Qual Life Res. 2014 Nov 13. [Epub ahead of print]. Prevalence of monoclonal gammopathy in HIV patients in 2014. Genet P et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19649. doi: 10.7448/IAS.17.4.19649. eCollection 2014.…
DetailsCarfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. Sullivan MR et al. J Clin Apher. 2014 Nov 21. doi: 10.1002/jca.21371. [Epub ahead of print]. A case of endocapillary proliferative glomerulonephritis with macrophages phagocytosing monoclonal immunoglobulin lambda light chain. Watanabe H et al. Pathol Int. 2014 Nov 19. doi: 10.1111/pin.12229. [Epub ahead of print]. Successful re-administration of lenalidomide after lenalidomide-induced…
DetailsSubcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Ong SY et al. Br J Haematol. 2014 Nov 21. doi: 10.1111/bjh.13238. [Epub ahead of print]. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Clark RE et al. Blood…
DetailsIn this guidance NICE outlines recommendations for the use of erythropoiesis-stimulating agents for the treatment of anaemia in cancer patients undergoing chemotherapy.
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. Mathis S et al. Cytometry B Clin Cytom. 2014 Oct 28. doi: 10.1002/cytob.21200. [Epub ahead of print]. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of…
DetailsUnveiling Skeletal Fragility in Patients Diagnosed with MGUS: No Longer a Condition of Undetermined Significance? Drake MT. J Bone Miner Res. 2014 Oct 15. doi: 10.1002/jbmr.2387. [Epub ahead of print]. A systemic disease un…suspected by physical examination. Costa C et al. BMJ Case Rep. 2014 Oct 9;2014. pii: bcr2014205919. doi: 10.1136/bcr-2014-205919. How I treat smoldering…
DetailsPanobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma candidates to autologous transplant. Mangiacavalli S et al. Leuk Lymphoma. 2014 Oct 27:1-8. [Epub ahead of print]. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Lau IJ…
Details